Bridge Technology Group LLC Announces Investment Opinion on Access Pharmaceuticals.NEW YORK--(BUSINESS WIRE)--Jan. 12, 1999-- Bridge Technology Group Llc Reiterates Buy Recommendation On Access Pharmaceuticals Inc. Following Acquisition of Product Rights Please Visit Bridge's Web Site at www.BridgeNYC.com for Detailed Report Bridge Technology Group LLC announced today that it has reiterated its BUY recommendation on Access Pharmaceuticals (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). :AXCS AXCS Senior Chief Aviation Antisubmarine Warfare Technician (Naval Rating) ) following AXCS' announcement that it had acquired rights from Block Drug Company to amlexanox for the indication of mucositis. The full text of this report can be accessed at Bridge's web site, at www.BridgeNYC.com. Amlexanox, in a 5% paste formulation, is currently the only FDA-approved product to treat canker sores Canker Sores Definition Canker sores are small sores or ulcers that appear inside the mouth. They are painful, self-healing, and can recur. Description (aphthous ulcers aphthous ulcer Canker sore Oral pathology A small, often painful mouth ulcer due to injury to the oral mucosal, viral infection or vitamin deficiency ) and is marketed by Block in the US as Aphthasol(tm). Mucositis involves ulceration ulceration /ul·cer·a·tion/ (ul?ser-a´shun) 1. the formation or development of an ulcer. 2. an ulcer. ul·cer·a·tion n. 1. Development of an ulcer. 2. of the mouth and is a common complication of chemotherapy (approximately 40% of patients) and virtually all patients who receive radiation therapy to the head and neck develop oral mucositis. The Bridge report estimates the U.S. market for amlexanox for the mucositis indication to be roughly $250 million and could be even greater if the product were to be used preventatively by cancer patients. Jeffrey B. Davis, President of Bridge Technology Group, stated, "We feel this is great news for Access, as management was able to acquire rights to a valuable product at a very reasonable cost to the company. We also believe that, due to the fact that amlexanox is already marketed for a similar indication and has an excellent safety profile, only an abbreviated Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA package on mucositis will be necessary to gain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval. We are estimating," Mr. Davis continued, "that Access will file an IND in the US and the UK during the first half of 1999, and that amlexanox for mucositis could receive US, UK and European approval during 2001." Bridge Technology Group LLC is focused on identifying emerging growth companies in the healthcare and information technology sectors that offer compelling investment opportunities over the long term. By providing comprehensive financial services The examples and perspective in this article or section may not represent a worldwide view of the subject. Please [ improve this article] or discuss the issue on the talk page. , including corporate finance, M&A advisory, strategic partnering and communications consulting, the company positions itself to provide a fully integrated package of value-added services A value-added service (VAS) is a telecommunications industry term for non-core services or, in short, all services beyond standard voice calls and fax transmissions. to emerging growth companies. The information in this press release has been obtained from sources that Bridge Technology Group LLC believes to be reliable, but the Company does not guarantee its accuracy or completeness. Neither the information nor any opinion expressed constitutes a solicitation by Bridge Technology Group LLC for the purchase or sale of any securities. Bridge Technology Group LLC may have performed investment banking, consulting or other services for or may solicit investment banking, consulting or other business from, any company mentioned in this release. Bridge Technology Group LLC or persons associated with Bridge Technology Group LLC may at anytime be long or short any of the securities referred to herein and may make purchases or sales thereof while the Company's reports are in circulation or posted on the Bridge Technology Group LLC web site at www.BridgeNYC.com. This material, or any portion thereof, may not be reproduced without prior permission from Bridge Technology Group LLC. Bridge Technology Group LLC is not responsible for the contents of this document that is intended for electronic transmission and could be thus subjected to tampering tampering The adulteration of a thing. See Drug tampering. or alteration. Copyright (c) 1999 by Bridge Technology Group LLC. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion